{"id":45555,"date":"2023-06-01T07:25:14","date_gmt":"2023-06-01T07:25:14","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=45555"},"modified":"2023-06-03T20:51:15","modified_gmt":"2023-06-03T20:51:15","slug":"nhs-england-approves-use-of-f-taf-as-alternative-prep","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/45555","title":{"rendered":"NHS England approves use of F\/TAF as alternative PrEP"},"content":{"rendered":"<div>\n<p class=\"HTBsubhead2articletitle\"><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><strong>On 24 May 2023, NHS England updated guidelines on PrEP to include tenofovir alafenomide (TAF) as a component of PrEP.<\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">Previously, PrEP was only reimbursed for generic formulations of tenofovir disoproxil (TD).<\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">In both cases, TD or TAF need to be used in a combination tablet that also includes emtricitabine (FTC).<\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">F\/TAF is now approved for cases where preexisting bone or kidney disease limits the use of TD.<\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">The paper estimates that this might affect from 400 to 700 people currently in need of this second-line PrEP. This estimate is based on 40,000 to 70,000 people currently using PrEP in the UK.<\/p>\n<\/div>\n<div>\n<p class=\"HTBreference-noindent\"><span lang=\"EN-US\">Reference<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBreference-noindent\"><span lang=\"EN-US\">NHS England. Reimbursement for the use of generic drugs for pre exposure prophylaxis (PrEP) for the prevention of HIV. (24 May 2023).<br \/>\n<\/span><a href=\"https:\/\/www.england.nhs.uk\/publication\/reimbursement-for-the-use-of-generic-drugs-for-pre-exposure-prophylaxis-prep-for-the-prevention-of-hiv\/\"><span lang=\"EN-GB\">https:\/\/www.england.nhs.uk\/publication\/reimbursement-for-the-use-of-generic-drugs-for-pre-exposure-prophylaxis-prep-for-the-prevention-of-hiv\/<\/span><\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base On 24 May 2023, NHS England updated guidelines on PrEP to include tenofovir alafenomide (TAF) as a component of PrEP. Previously, PrEP was only reimbursed for generic formulations of tenofovir disoproxil (TD). In both cases, TD &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[],"class_list":["post-45555","post","type-post","status-publish","format-standard","hentry","category-transmission-and-prevention"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/45555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=45555"}],"version-history":[{"count":3,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/45555\/revisions"}],"predecessor-version":[{"id":45668,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/45555\/revisions\/45668"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=45555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=45555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=45555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}